188 320
[21]
Kasel-Seibert M, Lehmann T, Aschenbach R, et al. Assessment of PI- RADS v2 for the detection of prostate cancer. Eur J Radiol 2016;85:726–31.
[22]
Lin WC, Muglia VF, Silva GE, Chodraui Filho S, Reis RB, Westphalen AC, Multiparametric MRI. of the prostate: diagnostic performance and interreader agreement of two scoring systems. Br J Radiol 2016;89:20151056.[23] Martorana E, Pirola GM, Scialpi M, et al. Lesion volume predicts
prostate cancer risk and aggressiveness: validation of its value
alone and matched with Prostate Imaging Reporting and Data
System score. BJU Int. In press.
http://dx.doi.org/10.1111/bju. 13649 .[24]
Mertan FV, Greer MD, Shih JH, et al. Prospective evaluation of the Prostate Imaging Reporting and Data System version 2 for prostate cancer detection. J Urol 2016;196:690–6.[25]
Muller BG, Shih JH, Sankineni S, et al. Prostate cancer: interobserver agreement and accuracy with the revised Prostate Imaging Report- ing and Data System at multiparametric MR imaging. Radiology 2015;277:741–50.[26]
Park JJ, Park BK. Role of PI-RADSv2 with multiparametric MRI in determining who needs active surveillance or definitive treat- ment according to PRIAS. J Magn Reson Imaging 2017;45: 1753–9.[27]
Park SY, Jung DC, Oh YT, et al. Prostate cancer: PI-RADS version 2 helps preoperatively predict clinically significant cancers. Radi- ology 2016;280:108–16.
[28]
Polanec S, Helbich TH, Bickel H, et al. Head-to-head comparison of PI-RADS v2 and PI-RADS v1. Eur J Radiol 2016;85:1125–31.
[29]
Rastinehad AR, Waingankar N, Turkbey B, et al. Comparison of multiparametric MRI scoring systems and the impact on cancer detection in patients undergoing MR US fusion guided prostate biopsies. PLoS One 2015;10:e0143404.
[30] Rosenkrantz AB, Babb JS, Taneja SS, Ream JM. Proposed adjustments
to PI-RADS version 2 decision rules: impact on prostate cancer
detection. Radiology. In press.
http://dx.doi.org/10.1148/radiol. 2016161124 .[31]
Stanzione A, Imbriaco M, Cocozza S, et al. Biparametric 3T magnetic resonance imaging for prostatic cancer detection in a biopsy-naive patient population: a further improvement of PI-RADS v2? Eur J Radiol 2016;85:2269–74.
[32] Tan N, Lin WC, Khoshnoodi P, et al. In-Bore 3-T MR-guided trans-
rectal targeted prostate biopsy: Prostate Imaging Reporting and
Data System version 2-based diagnostic performance for detection
of prostate cancer. Radiology. In press.
http://dx.doi.org/10.1148/ radiol.2016152827.
[33]
Tewes S, Mokov N, Hartung D, et al. Standardized reporting of prostate MRI: comparison of the Prostate Imaging Reporting and Data System (PI-RADS) version 1 and version 2. PLoS One 2016;11:e0162879.
[34]
Washino S, Okochi T, Saito K, et al. Combination of PI-RADS score and PSA density predicts biopsy outcome in biopsy naive patients. BJU Int 2017;119:225–33.[35]
Woo S, Kim SY, Lee J, Kim SH, Cho JY. PI-RADS version 2 for prediction of pathological downgrading after radical prostatec- tomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3 + 4) prostate cancer. Eur Radiol 2016;26:3580–7.[36]
Zhao C, Gao G, Fang D, et al. The efficiency of multiparametric magnetic resonance imaging (mpMRI) using PI-RADS Version 2 in the diagnosis of clinically significant prostate cancer. Clin Imaging 2016;40:885–8.
[37]
de Rooij M, Hamoen EH, Futterer JJ, Barentsz JO, Rovers MM. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. Am J Roentgenol 2014;202:343–51.
[38]
Shah ZK, Elias SN, Abaza R, et al. Performance comparison of 1.5-T endorectal coil MRI with 3.0-T nonendorectal coil MRI in patients with prostate cancer. Acad Radiol 2015;22:467–74.[39]
Mazaheri Y, Vargas HA, Nyman G, Akin O, Hricak H. Image artifacts on prostate diffusion-weighted magnetic resonance imaging: trade-offs at 1.5 Tesla and 3.0 Tesla. Acad Radiol 2013;20:1041–7.
[40]
Deeks JJ. Systematic reviews in health care: systematic reviews of evaluations of diagnostic and screening tests. BMJ 2001;323:157–62.[41] Deeks JJWS, Davenport C. Guide to the contents of a Cochrane
diagnostic test accuracy protocol. In: Deeks JJ, Bossuyt PM, Gatsonis
C, editors. Cochrane handbook for systematic reviews of diagnostic
test accuracy version 1.0.0. Chapter 4. The Cochrane Collaboration;
2013
In: http://srdta.cochrane.org/.E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) 1 7 7 – 1 8 8
188